

Notice of References CitedApplication/Control No.
10/508,898Applicant(s)/Patent Under
Reexamination
BROCKUNIER ET AL.Examiner
Sun Jae Y. LoeweArt Unit
1609

Page 1 of 5

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	http://en.wikipedia.org/wiki/Atherosclerosis , p.1-3 of 3 ✓
	V	http://en.wikipedia.org/wiki/Retinopathy , p. 1 of 2 (1 page) ✓
	W	Wiedeman et al., "Dipeptidyl peptidase IV inhibitors for type 2 diabetes and metabolic syndrome", Drug Discovery Today: Therapeutic Strategies, 2005, vol2, p.143-149 ✓
	X	McIntosh et al., "Dipeptidyl peptidase IV inhibitors: How do they work as new antidiabetic agents?", Regulatory Peptides, 128 (2005), 159-165. ✓

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Notice of References Cited	Application/Control No. 10/508,898	Applicant(s)/Patent Under Reexamination BROCKUNIER ET AL.	
	Examiner Sun Jae Y. Loewe	Art Unit 1609	Page 2 of 5

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Ahren et al., "Inhibition of Dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes", The Journal of Clinical Endocrinology & metabolism, 89(2): 2078-2084 ✓
	V	http://en.wikipedia.org/wiki/Hyperglycemia , pg1-2 of 4 ✓ (2 pages enclosed)
	W	http://en.wikipedia.org/wiki/Diabetes_mellitus_type_1 , pg1 of 6 ✓ (1 page enclosed) ✓
	X	Augeri et al., "Discovery and Preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes", J. Med. Chem. 2005, 48, 5025-5037 ✓

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Notice of References Cited	Application/Control No. 10/508,898	Applicant(s)/Patent Under Reexamination BROCKUNIER ET AL.	
	Examiner Sun Jae Y. Loewe	Art Unit 1609	Page 3 of 5

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	http://dictionary.reference.com/browse/prophylaxis , p.2 of 4 (1 page enclosed)
	V	http://www.webmd.com/hypertension-high-blood-pressure/guide/preventing-high-blood-pr... , pg.1-2 of 2
	W	http://www.webmd.com/diet/tc/Obesity-Overview , pg.1-2 of 3 (2 pages enclosed)
	X	http://diabetes.webmd.com/guide/insulin-resistance.syndrome , p.1 of 1 ✓

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Notice of References Cited

Application/Control No.

10/508,898

Applicant(s)/Patent Under
Reexamination
BROCKUNIER ET AL.

Examiner

Sun Jae Y. Loewe

Art Unit

1609

Page 4 of 5

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	http://diabetes.webmd.com/guide/preventing-type-2-diabetes , pg.1-2 of 3 (2 pages enclosed)
	L V	Erez et al., "The rationale for using HMG-CoA reductase inhibitors ('statins') in peripheral arterial disease", Eur. J. Vasc. Endovasc. Surg., 33, 192-201 (2007) ✓
	W	Rieusset et al., A New Selective Peroxisome Proliferator-Activated Receptor gamma Antagonist with Antiobesity and Antidiabetic Activity, abstract (pages 1 and 2 of 6), 2 pages enclosed
	X	He et al., Adipose-specific peroxisome proliferator-activated receptor (gamma) knockout causes insulin resistance in fat and liver but not in muscle, PNAS, vol 100, no. 26, pages 15712-15717.

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Notice of References Cited	Application/Control No. 10/508,898	Applicant(s)/Patent Under Reexamination BROCKUNIER ET AL.	
	Examiner Sun Jae Y. Loewe	Art Unit 1609	Page 5 of 5

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Ryan et al., PPAR gamma Agonist Rosiglitazone Improves Vascular Function and Lowers Blood Pressure in Hypertensive Transgenic Mice, abstract (pages 1 and 2 of 4), <i>2 pages enclosed</i>
	V	Hung et al., Rosiglitazone improves insulin sensitivity and glucose tolerance in subjects with impaired glucose tolerance, abstract (pages 1 and 2 of 3), <i>2 pages enclosed</i>
	W	Chapman, J. M., "Therapeutic Elevation of HDL-cholesterol to prevent atherosclerosis and coronary hear disease", Pharmacology and Therapeutics, 111 (2006), 893-908
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.